CLL2-BIG:苯达莫司汀、伊布替尼和奥妥珠单抗(GA101)序贯治疗慢性淋巴细胞白血病
探索性CLL2-BIG试验评估苯达莫司汀减瘤后伊布替尼联合奥妥珠单抗诱导、再以微小残留病触发维持的序贯方案,纳入61例慢性淋巴细胞白血病患者(30例初治、31例复发/难治),诱导结束时总缓解率100%,47.5%患者外周血微小残留病不可检出(<10⁻⁴)。
要点
- 诱导期最常见3-4级不良事件为中性粒细胞减少(14.8%)和血小板减少(13.1%),发生1例死亡(十二指肠炎)。
- 总缓解率100%,部分缓解54.1%,临床完全缓解41%,临床完全缓解伴骨髓不完全恢复4.9%。
- 47.5%患者外周血流式细胞术检测微小残留病不可检出(<10⁻⁴)。
核心结论
- BIG方案是治疗慢性淋巴细胞白血病安全且高度有效的方案。
研究设计与样本
- 探索性CLL2-BIG试验采用序贯联合策略:高肿瘤负荷者先接受2周期苯达莫司汀减瘤,随后6周期伊布替尼联合GA101诱导,再进入微小残留病触发的维持阶段。
- 共纳入61例慢性淋巴细胞白血病患者,其中30例既往未治疗,31例为复发/难治;44例接受了苯达莫司汀。
- 本文报告诱导阶段结束时预设分析的结果。
主要发现
- 诱导期间最常见的CTC 3级和4级事件为中性粒细胞减少(14.8%)和血小板减少(13.1%)。
- 发生1例死亡(十二指肠炎)。
- 总缓解率为100%;54.1%患者达部分缓解,41%达临床完全缓解(按方案未经CT扫描或骨髓活检确认),4.9%达临床完全缓解伴骨髓不完全恢复。
- 29例患者(47.5%)外周血流式细胞术检测微小残留病不可检出(<10⁻⁴)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obinutuzumab (GA101) and ibrutinib show excellent efficacy for treatment of chronic lymphocytic leukemia (CLL). Preclinical investigations and a complementary safety profile were in support of testing their combined use. The exploratory CLL2-BIG-trial evaluated a sequential combination therapy following a recently proposed strategy. Two courses of bendamustine were used for debulking in patients with a high tumor load, followed by six courses of induction therapy with ibrutinib and GA101, followed by an MRD-triggered maintenance phase. The results of a pre-planned analysis at the end of the induction phase are presented. 61 patients were included, 30 previously untreated and 31 with relapsed/refractory CLL. 44 patients received bendamustine. During induction, neutropenia (14.8%) and thrombocytopenia (13.1%) were the most common CTC grade 3 and 4 events. One fatality (duodenitis) occurred. The overall response rate was 100%. 54.1% of patients achieved a partial remission, 41% a clinical complete remission (cCR) without confirmation by CT scan or bone marrow (BM) biopsy according to protocol and 4.9% a cCR with incomplete recovery of the BM. 29 patients (47.5%) had no detectable (<10-4) minimal residual disease assessed by flow cytometry in peripheral blood. In conclusion, the BIG regimen is a safe and highly effective therapy for CLL.
引用
- von Tresckow J, Cramer P, Bahlo J, et al. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2018. PMID: 30568174. doi:10.1038/s41375-018-0313-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。